Buchumschlag

Prevention and management of CMV infections after liver transplantation: current practice in German transplant centers

Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Engelmann, Cornelius (VerfasserIn) , Sterneck, Martina (VerfasserIn) , Weiss, Karl Heinz (VerfasserIn) , Templin, Silke (VerfasserIn) , Zopf, Steffen (VerfasserIn) , Denk, Gerald Ulrich (VerfasserIn) , Eurich, Dennis (VerfasserIn) , Pratschke, Johann (VerfasserIn) , Weiß, Johannes (VerfasserIn) , Braun, Felix (VerfasserIn) , Welker, Martin-Walter (VerfasserIn) , Zimmermann, Tim (VerfasserIn) , Knipper, Petra (VerfasserIn) , Nierhoff, Dirk (VerfasserIn) , Lorf, Thomas (VerfasserIn) , Jäckel, Elmar (VerfasserIn) , Hau, Hans-Michael (VerfasserIn) , Tsui, Tung Yu (VerfasserIn) , Perrakis, Aristotelis (VerfasserIn) , Schlitt, Hans Jürgen (VerfasserIn) , Herzer, Kerstin (VerfasserIn) , Tacke, Frank (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 23 July 2020
In: Journal of Clinical Medicine
Year: 2020, Jahrgang: 9, Heft: 8
ISSN:2077-0383
DOI:10.3390/jcm9082352
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/jcm9082352
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2077-0383/9/8/2352
Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465768
Volltext
Verfasserangaben:Cornelius Engelmann, Martina Sterneck, Karl Heinz Weiss, Silke Templin, Steffen Zopf, Gerald Denk, Dennis Eurich, Johann Pratschke, Johannes Weiss, Felix Braun, Martin-Walter Welker, Tim Zimmermann, Petra Knipper, Dirk Nierhoff, Thomas Lorf, Elmar Jäckel, Hans-Michael Hau, Tung Yu Tsui, Aristoteles Perrakis, Hans-Jürgen Schlitt, Kerstin Herzer, Frank Tacke
Beschreibung
Zusammenfassung:Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90% of centers, transient prophylaxis with ganciclovir or valganciclovir was standard of care in high-risk (donor CMV positive, recipient CMV naive) settings, while preemptive therapy (based on CMV viremia detected during (bi) weekly PCR testing for circulating CMV-DNA) was preferred in moderate- and low-risk settings. Duration of prophylaxis or intense surveillance was 3–6 months. In the case of CMV infection, immunosuppression was adapted. In most centers, antiviral treatment was initiated based on PCR results (median threshold value of 1000 copies/mL) with or without symptoms. Therefore, German transplant centers report similar approaches to the prevention and management of CMV infection in liver transplantation.
Beschreibung:Gesehen am 15.03.2020
Beschreibung:Online Resource
ISSN:2077-0383
DOI:10.3390/jcm9082352

Ähnliche Einträge